At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 306 enrolled
Drug / intervention
Anacetrapib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia
In Brief
A Phase 3 clinical trial evaluating Anacetrapib and Placebo for Hyperlipoproteinemia Type II and Hypercholesterolemia, Familial. Completed, enrolled 306 participants.
Detailed Summary
The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartFeb 2012
Primary CompletionFeb 2014
Study CompletionNov 2018
TodayJul 2026
First PostedFeb 1, 2012
Enrollment StartFeb 3, 2012
Primary CompletionFeb 12, 2014
Study CompletionNov 13, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 14.4 years ago
Interventions
Anacetrapibdrug
One oral tablet, orally once daily for 52 weeks
Placebodrug
One oral tablet once daily for 52 weeks